Anticoagulant Efficacy of Solid Oral Formulations Containing a New Heparin Derivative
Authors:
- Jin Woo ParkJPJin Woo Park
- Ok Cheol JeonOJOk Cheol Jeon
- Sang Kyoon KimSKSang Kyoon Kim
- Taslim Ahmed Al-HilalTATaslim Ahmed Al-Hilal
- Hyun Tae MoonHMHyun Tae Moon
- Choong Yong KimCKChoong Yong Kim
- Youngro ByunYBYoungro Byun
- 29 March 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 7 (3) , 836-843
Abstract
The need for an efficacious and safe oral anticoagulant that does not require monitoring has been largely unmet. Many efforts have centered on preparing orally available heparin to improve patient compliance. In this study, novel orally active heparin derivatives (LHD), i.e. low molecular weight heparin (LMWH) conjugated with deoxycholic acid (DOCA), were evaluated in vitro and in vivo for their enhancement effect of oral heparin absorption. After oral administration of 10 mg/kg of water-soluble LHD, Ws-LHD1.5 showed optimum oral efficacy and its bioavailability was about 24% in rats. The oral absorption of LHD1.5 was also enhanced by several solubilizers, among which Poloxamer 407 provided the best results. When 5 mg/kg of LHD1.5 with Poloxamer 407 was orally administered to monkeys, the maximum anti-FXa activity in plasma was 0.26 ± 0.04 IU/mL and its bioavailability was 17.4%. In a rat thrombosis model, 5 mg/kg of orally administered LHD1.5 formulated with Poloxamer reduced thrombus formation by 63.9 ± 16.6%, which was higher than the efficacy of clinically used enoxaparin (49.4 ± 17.8% at 100 IU/kg, sc). Considering the oral absorption efficacy and therapeutic effect, the conjugation ratio was optimized as about 1.5 molecules of DOCA per mole of heparin. Therefore, LHD1.5 with Poloxamer 407 can be further formulated as a solid oral anticoagulant drug.Keywords
This publication has 24 references indexed in Scilit:
- Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studiesInternational Journal of Pharmaceutics, 2006
- Oral bioavailability of a low molecular weight heparin using a polymeric delivery systemJournal of Controlled Release, 2006
- The quest for non-invasive delivery of bioactive macromolecules: A focus on heparinsJournal of Controlled Release, 2006
- Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugatesJournal of Controlled Release, 2005
- In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in RabbitsCirculation, 2002
- Guide to Anticoagulant Therapy: HeparinCirculation, 2001
- Mono‐N‐Carboxymethyl Chitosan (MCC), a Polyampholytic Chitosan Derivative, Enhances the Intestinal Absorption of Low Molecular Weight Heparin Across Intestinal Epithelia In Vitro and In VivoJournal of Pharmaceutical Sciences, 2001
- The effect of physical barriers and properties on the oral absorption of particulatesAdvanced Drug Delivery Reviews, 1998
- 9 Anticoagulants in the prevention of venous thromboembolismBailliere's Clinical Haematology, 1990
- Oral administration of liposomally-entrapped heparin to beagle dogs.Chemical and Pharmaceutical Bulletin, 1982